China’s EV Sector Is ‘Absolutely Booming,’ Says Standard Chartered CEO

Despite a general slowdown in China's post-Covid economic rebound, Winters noted that the country is making strides toward a more robust and sustainable economy.

Amid China’s uneven economic recovery, the electric vehicle (EV) sector is witnessing a remarkable surge, according to the CEO of Standard Chartered, Bill Winters.

Winters highlighting the exceptional growth of China’s EV sector, reported CNBC. While speaking at the Global Financial Leaders’ Investment Summit, Winters described the sector as “absolutely booming,” in stark contrast to the broader economic challenges facing the nation.

Despite a general slowdown in China’s post-Covid economic rebound, Winters noted that the country is making strides toward a more robust and sustainable economy. This includes a strategic shift from traditional industries to burgeoning sectors like renewable power technologies and electric vehicles.

See Also: Roblox Q3 Earnings Preview: Analyst Estimates, Key Items To Watch For Gaming Giant

China’s dominance in the EV market is backed by impressive sales figures. In 2022, the country accounted for 59% of global EV sales, with 5.9 million units sold. Local brands, which represent 81% of the domestic EV market share, include giants such as BYD (OTC:BYDDF), Wuling (OTC:WLTMF), and Chery.

The news arrives amid a backdrop of a struggling Chinese property market, with major firms like Evergrande and Country Garden battling significant debt challenges.

Winters expressed caution regarding the property market’s outlook but indicated that the situation might be approaching a turning point. Meanwhile, the bank continues to see robust growth in other key markets, with Hong Kong serving as a pivotal center for its offshore business, experiencing an annual growth rate of 50% to 60%.

Read Next: Is It Time To Buy Nio?

Photo via Shutterstock


Engineered by
Benzinga Neuro, Edited by


Pooja Rajkumari


The GPT-4-based Benzinga Neuro content generation system exploits the
extensive Benzinga Ecosystem, including native data, APIs, and more to
create comprehensive and timely stories for you.
Learn more.


Total
0
Shares
Related Posts
Read More

Allogene Therapeutics’ Allogeneic CAR-T Therapy Proves Potential for LBCL Treatment, Analysts See Potential for First-in-Class Status

Thursday, Allogene Therapeutics Inc (NASDAQ: ALLO) presented the updated data from the Phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A in 33 CAR T naïve patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL) treated with the Alloy manufacturing process material across different&nbs

ALLO

Read More

LianBio Announces China National Medical Products Administration Acceptance With Priority Review Of New Drug Application For Mavacamten For The Treatment Of Patients With Obstructive Hypertrophic Cardiomyopathy

LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that China's National Medical Products Administration

LIAN